Actively Recruiting
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Led by Ruijin Hospital · Updated on 2025-08-26
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
R
Ruijin Hospital
Lead Sponsor
J
Jiangsu HengRui Medicine Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
CONDITIONS
Official Title
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, male or female
- Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas with at least one measurable lesion
- Imaging shows resectable or borderline resectable pancreatic cancer as defined by NCCN guidelines
- ECOG Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate bone marrow and organ function
- Female participants of childbearing age must have a negative pregnancy test within one week before starting treatment and agree to use effective contraception during the study and for three months after
- Male participants with partners of childbearing potential must agree to use effective contraception during the study and for six months after
- Voluntary agreement to participate and signed informed consent
You will not qualify if you...
- Previous anti-tumor therapy
- Presence of distant metastatic lesions
- Known allergy to the study drug or its components
- Previous or current other malignant tumors
- Participation in another clinical trial of a drug or device within four weeks before the first dose
- Received live or attenuated vaccines within four weeks before the first dose
- Previous allogeneic stem cell or organ transplant
- Severe cardiovascular events or conditions including myocardial infarction, unstable angina, stroke, or significant arrhythmias
- Interstitial lung disease, non-infectious pneumonia, severe uncontrolled illness, acute infections, or recent major surgery within 28 days
- Congenital or acquired immunodeficiencies such as HIV infection, active hepatitis B or C, or co-infection with hepatitis B and C
- Clinically significant acute or chronic pancreatitis or high risk for pancreatitis
- Other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here